Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice. Antioxidants (Basel) 2021 Aug 25;10(9)
Date
09/29/2021Pubmed ID
34572970Pubmed Central ID
PMC8472607DOI
10.3390/antiox10091338Scopus ID
2-s2.0-85113363981 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Plaque psoriasis is a common inflammatory condition of the skin characterized by red, flaking lesions. Current therapies for plaque psoriasis target many facets of the autoimmune response, but there is an incomplete understanding of how oxidative damage produced by enzymes such as myeloperoxidase contributes to skin pathology. In this study, we used the Aldara (Imiquimod) cream model of plaque psoriasis in mice to assess myeloperoxidase inhibition for treating psoriatic skin lesions. To assess skin inflammation severity, an innovative mouse psoriasis scoring system was developed. We found that myeloperoxidase inhibition ameliorated psoriasis severity when administered either systemically or topically. The findings of this study support the role of oxidative damage in plaque psoriasis pathology and present potential new therapeutic avenues for further exploration.
Author List
Neu SD, Strzepa A, Martin D, Sorci-Thomas MG, Pritchard KA Jr, Dittel BNAuthors
Kirkwood A. Pritchard PhD Professor in the Surgery department at Medical College of WisconsinMary Sorci Thomas PhD Professor in the Medicine department at Medical College of Wisconsin
